CA2323831A1 - Vecteurs de transfert d'acides nucleiques, compositions les contenant, et leurs utilisations - Google Patents

Vecteurs de transfert d'acides nucleiques, compositions les contenant, et leurs utilisations Download PDF

Info

Publication number
CA2323831A1
CA2323831A1 CA002323831A CA2323831A CA2323831A1 CA 2323831 A1 CA2323831 A1 CA 2323831A1 CA 002323831 A CA002323831 A CA 002323831A CA 2323831 A CA2323831 A CA 2323831A CA 2323831 A1 CA2323831 A1 CA 2323831A1
Authority
CA
Canada
Prior art keywords
nucleic acid
sequence
acid transfer
transfer vector
oligonucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002323831A
Other languages
English (en)
French (fr)
Inventor
Carole Ciolina
Daniel Scherman
Pierre Wils
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9803573A external-priority patent/FR2776669B1/fr
Application filed by Individual filed Critical Individual
Publication of CA2323831A1 publication Critical patent/CA2323831A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA002323831A 1998-03-24 1999-03-19 Vecteurs de transfert d'acides nucleiques, compositions les contenant, et leurs utilisations Abandoned CA2323831A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR9803573A FR2776669B1 (fr) 1998-03-24 1998-03-24 Vecteurs de transfert d'acides nucleiques, compositions les contenant, et leurs utilisations
FR9803573 1998-03-24
US8584898P 1998-05-18 1998-05-18
US60/085848 1998-05-18
PCT/FR1999/000643 WO1999049067A1 (fr) 1998-03-24 1999-03-19 Vecteurs de transfert d'acides nucleiques, compositions les contenant, et leurs utilisations

Publications (1)

Publication Number Publication Date
CA2323831A1 true CA2323831A1 (fr) 1999-09-30

Family

ID=26234216

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002323831A Abandoned CA2323831A1 (fr) 1998-03-24 1999-03-19 Vecteurs de transfert d'acides nucleiques, compositions les contenant, et leurs utilisations

Country Status (12)

Country Link
EP (1) EP1066396A1 (zh)
JP (1) JP2002507429A (zh)
KR (1) KR20010074456A (zh)
CN (1) CN1292827A (zh)
AU (1) AU758406B2 (zh)
BR (1) BR9909044A (zh)
CA (1) CA2323831A1 (zh)
HU (1) HUP0102413A3 (zh)
IL (1) IL138624A0 (zh)
NO (1) NO20004648D0 (zh)
PL (1) PL342944A1 (zh)
WO (1) WO1999049067A1 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6345901A (en) 2000-05-26 2001-12-11 Aventis Pharma Sa Purification of a triple heli formation with an immobilized oligonucleotide
FR2871465B1 (fr) * 2004-06-15 2006-09-08 Centre Nat Rech Scient Cnrse Collections de composes tracables et leurs utilisations
WO2006133099A2 (en) * 2005-06-03 2006-12-14 The Cbr Institute For Biomedical Research, Inc. Sirna microbicides for preventing and treating viral diseases
US7795380B2 (en) 2006-06-02 2010-09-14 University Of Iowa Research Foundation Compositions and methods for nucleic acid delivery
US11237163B2 (en) * 2016-03-07 2022-02-01 Quidel Cardiovascular Inc. Immunoassay controls and the use thereof
RU2731513C2 (ru) * 2018-12-21 2020-09-03 Селл энд Джин Терапи Лтд Генотерапевтический ДНК-вектор на основе генотерапевтического ДНК-вектора VTvaf17, несущий целевой ген, выбранный из группы генов NOS2, NOS3, VIP, KCNMA1, CGRP, для повышения уровня экспрессии этих целевых генов, способ его получения и применения, штамм Escherichia coli SCS110-AF/VTvaf17-NOS2, или Escherichia coli SCS110-AF/VTvaf17-NOS3, или Escherichia coli SCS110-AF/VTvaf17-VIP, или Escherichia coli SCS110-AF/VTvaf17-KCNMA1, или Escherichia coli SCS110-AF/VTvaf17-CGRP, несущий генотерапевтический ДНК-вектор, способ его получения, способ производства в промышленных масштабах генотерапевтического ДНК-вектора
WO2024206118A1 (en) * 2023-03-24 2024-10-03 Yarrow Therapeutics, Inc. Nuclear localization polypeptides and conjugates and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992020698A1 (en) * 1991-05-17 1992-11-26 Uab Research Foundation Sequence specific dna binding drugs
US5670347A (en) * 1994-05-11 1997-09-23 Amba Biosciences Llc Peptide-mediated gene transfer
FR2731014B1 (fr) * 1995-02-23 1997-03-28 Rhone Poulenc Rorer Sa Molecules d'adn, preparation et utilisation en therapie genique

Also Published As

Publication number Publication date
IL138624A0 (en) 2001-10-31
PL342944A1 (en) 2001-07-16
HUP0102413A1 (hu) 2001-10-28
HUP0102413A3 (en) 2003-09-29
JP2002507429A (ja) 2002-03-12
AU3406200A (en) 2000-12-14
NO20004648L (no) 2000-09-18
NO20004648D0 (no) 2000-09-18
EP1066396A1 (fr) 2001-01-10
BR9909044A (pt) 2000-12-05
KR20010074456A (ko) 2001-08-04
AU758406B2 (en) 2003-03-20
CN1292827A (zh) 2001-04-25
WO1999049067A1 (fr) 1999-09-30

Similar Documents

Publication Publication Date Title
EP0809705B1 (fr) Compositions contenant des acides nucleiques, preparation et utilisation
CA2194797C (fr) Composition contenant des acides nucleiques, preparation et utilisations
EP0738328B1 (fr) Composition contenant des acides nucleiques, preparation et utilisations
US7279326B2 (en) Composition for delivery of a mitochondrial genome to a cell
US20210322577A1 (en) Methods and systems for modifying dna
KR20010034493A (ko) 고지혈증의 유전자 치료를 위한 방법 및 조성물
AU2002255285A1 (en) Circular dumbbell decoy oligodeoxynucleotides (cdodn) containing dna bindings sites of transcription
FR2750704A1 (fr) Procede de production d'adn therapeutique
WO2023283246A1 (en) Modular prime editor systems for genome engineering
CA2323831A1 (fr) Vecteurs de transfert d'acides nucleiques, compositions les contenant, et leurs utilisations
WO1997012051A1 (fr) Composition pharmaceutique utile pour la transfection d'acides nucleiques et ses utilisations
JP2002533088A (ja) 非病原性トランスフェクションベクター
FR2776669A1 (fr) Vecteurs de transfert d'acides nucleiques, compositions les contenant, et leurs utilisations
AU2018286393A2 (en) Genome editing system for repeat expansion mutation
Sierakowska et al. Restoration of ß-globin gene expression in mammalian cells by antisense oligonucleotides that modify the aberrant splicing patierns of thalassemic pre-mRNAs
CN117384883B (zh) CRISPR-Cas系统及其应用
Weber-Lotfi et al. Targeting Therapeutic Nucleic Acids into Mitochondria: A Long Challenge
CN117964776A (zh) 基因编辑融合蛋白、基因编辑系统及其应用
WO2010023544A1 (en) Compositions and methods for delivery of protein-coding rnas to correct mitochondrial dysfunction
EP0895542A1 (fr) Systeme d'expression derive du gene de la tyrosine hydroxylase
MXPA00009046A (en) Nucleic acid transfer vectors, compositions containing same and uses
CZ20003441A3 (cs) Vektory pro přenos nukleových kyselin, přípravky, které je obsahují a jejich použití
WO2002096928A2 (fr) Vecteur peptidique pour le transfert de molecules d'interêt dans des cellules eucaryotes

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued